Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70208 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Mario Hlevnjak und 31 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital H…. Hauptthemen laut MEDLINE: Precision Medicine, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid, Bundesministerium für Bildung und Forschung, National Center for Tumor Diseases Heidelberg, Molecular Precision Oncology Program.
Abstract (Originalsprache)
CATCH is a prospective precision oncology registry trial that exploits whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer (mBC) patients of any subtype. We herein report long‐term follow‐up of the first 558 patients consecutively recruited into CATCH in a monocentric setting between June 2017 and October 2021. Main outcome measures were the rate of implementation of molecular tumor board (MTB) recommended treatments and treatment response as assessed by disease control rate, objective response rate and PFS ratio. Out of the recruited patients, 412 (54.9% HR+/HER2−, 31.3% TNBC, 6.8% HR−/HER2+ and 7.0% HR+/HER2+) were reviewed in the MTB. An appropriate molecularly guided anti‐cancer treatment as recommended by MTB was implemented in 183 (44.4%) patients. Gene expression and computationally derived composite biomarkers further expanded treatment options in up to every second patient as compared to genomic sequencing data alone. The outcome was assessed in 152 patients and showed a Disease Control Rate (DCR) of 58.6% and an Objective Response Rate (ORR) of 27.0%. One in three patients (32.8%) showed at least a 50% longer PFS with molecularly guided therapy compared to the previous standard therapy. Notably, 86.4% of the MTB‐driven implementations were off‐label. CATCH highlights the impact of whole‐genome/exome in combination with RNA sequencing to detect clinically relevant biomarkers in mBC. Omics‐guided targeted therapy in a real‐world setting allows high treatment implementation rates yielding outcome benefit for one‐third of the patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg Uni…
- Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany.
- National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg University, and The Thorax Clinic Heidelb…
- Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
- Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Medical Oncology, National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ, The University Hospital Heidelberg (UKHD), The Heidelberg Medical Faculty of the Heidelberg Universit…
ORCID-Profile: Stefan Fröhling, Hans-Peter Sinn, Albrecht Stenzinger, Marc Zapatka, Peter Lichter
Förderung
- German Cancer Aid
- Bundesministerium für Bildung und Forschung
- National Center for Tumor Diseases Heidelberg, Molecular Precision Oncology Program
- Deutsche Krebshilfe
- Bundesministerium für Forschung, Technologie und Raumfahrt
Zitieren
APA
Hlevnjak, M., Heublein, S., Thewes, V., Wagener, L., Pixberg, C., Fremd, C., Michel, L., Maurer, C., Buschhorn, L., Dikow, N., Feng, F., Fröhling, S., Herold-Mende, C., Hirsch, S., Hong, C., Hübschmann, D., Jassowicz, L., Kozyulina, P., Pfütze, K., …, & Lichter, P. (2026). Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience. International Journal of Cancer. https://doi.org/10.1002/ijc.70208
Vancouver
Hlevnjak M, Heublein S, Thewes V, Wagener L, Pixberg C, Fremd C, et al. Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience. International Journal of Cancer. 2026. doi:10.1002/ijc.70208
BibTeX
@article{Hlevnjak2026,
author = {Hlevnjak, Mario and Heublein, Sabine and Thewes, Verena and Wagener, Lukas and Pixberg, Constantin and Fremd, Carlo and Michel, Laura and Maurer, Christian and Buschhorn, Lars and Dikow, Nicola and Feng, Fangyoumin and Fröhling, Stefan and Herold-Mende, Christel and Hirsch, Steffen and Hong, Chen and Hübschmann, Daniel and Jassowicz, Lena and Kozyulina, Polina and Pfütze, Katrin and Schlenk, Richard F and Sinn, Hans-Peter and Smetanay, Katharina and Springfeld, Christoph and Stenzinger, Albrecht and Wagner, Celina and Wolf, Stephan and Trumpp, Andreas and Jäger, Dirk and Zivanovic, Oliver and Zapatka, Marc and Schneeweiss, Andreas and Lichter, Peter},
title = {Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70208}
}
EUVIMED